{"createdAt":"8/2/2020, 2:36:55 PM","timestamp":1596393415956,"Company ID number":"642","DMX_ISSUER_NAME":"Sichuan Kelun Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002591999","Country of Classification":"CHINA","name":"Sichuan Kelun Pharmaceutical Co Ltd ","code":"002422","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"四川科伦药业股份有限公司_刘革新","group":"board","name":"刘革新","title":"董事长,董事","isMale":true,"age":"69","degree":"硕士","salary":"200.0万","stockAmount":"3.791亿","description":"刘革新先生,1951年出生,中国国籍,无境外居留权,公司董事长,党委书记,研究生学历,高级工程师。1992年任四川奇力制药有限公司总经理,1996年创建科伦大药厂,担任公司董事长至今。1996至2003年期间担任公司总经理,历任四川省工商联合会副会长,政协四川省第九届委员会常务委员,中共四川省第九次代表大会代表,第十一届全国政协委员,中国共产党成都市第十二次代表大会代表,中国共产党四川省第十次代表大会代表,第十二届全国人民代表大会代表。2005年,荣获“全国劳动模范”荣誉称号;2008年,荣获中共四川省委、成都市委授予的“抗震救灾优秀共产党员”光荣称号和四川省委、省政府授予的“抗震救灾模范”光荣称号;2009年,被中共中央统战部、工业和信息化部、人力资源和社会保障部、国家工商行政管理总局、全国工商联评为“优秀中国特色社会主义建设者”,2010年,获中共成都市委、成都市人大常委、成都市人民政府和政协成都市委颁发的“建设成都杰出贡献奖”,2015年作为项目第一完成人荣获国家科技进步二等奖。目前兼任四川科伦实业集团有限公司董事长和常熟恩赛生物科技有限公司副董事长。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_刘思川","group":"board","name":"刘思川","title":"董事","isMale":true,"age":"36","degree":"硕士","salary":"160.0万","stockAmount":"709.9万","description":"刘思川先生,1984年出生,中国国籍,无境外居留权,公司董事,总经理,硕士研究生学历。2007年起任公司董事长助理,2009年6月起任公司董事,2012年7月起任公司副总经理,2015年9月起任公司总经理。2013年1月当选为湖南省第十二届人民代表大会代表,2018年1月当选为湖南省第十三届人民代表大会代表。现为中华全国青年联合会委员,中国青年志愿者协会常务理事、中国光华科技基金会第六届理事会理事,全国工商联执行委员,湖南省总商会副会长。目前兼任四川科伦实业集团有限公司董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_王晶翼","group":"board","name":"王晶翼","title":"董事","isMale":true,"age":"60","degree":"博士","salary":"800.0万","stockAmount":"35.22万","description":"王晶翼先生,1960年出生,中国国籍,有境外居留权,公司副总经理、全球研发总裁、首席科学家、药物研究院院长,2015年9月起任公司董事。目前兼任四川科伦博泰生物医药股份有限公司董事长。中国医科大学77级临床医学本科,解放军第四军医大学传染病学硕士、医学分子病毒学博士。曾任美国阿肯色医科大学医学助理教授(Tenuretrack)、齐鲁制药有限公司集团副总经理和药物研究院院长,目前兼任《中国新药杂志》编委、国家科学技术奖励评审专家、重大新药创制国家科技重大专项评委等社会职务。近年来三次荣获国家科学技术进步二等奖。自2002年回国以来,王晶翼博士带领团队上市重大品种30余项,其中不乏卡培他滨等年销售额超过10亿的重磅药物,且有塞拉替尼等20余项创新药物相继步入临床研究。自2012年11月加盟科伦以后,在王晶翼院长的领导下,科伦的药物研究已从简单输液产品仿制研究转型为高技术内涵药物为主的研究;以“仿制为基础,创新驱动未来”的产品线战略布局全面达成;科伦已成为国内药品研发创新发展速度迅捷、体系完备的大型制药企业,成功构建了一支科学水平高、战斗意志强、与国际接轨的创新研发团队。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_张腾文","group":"board","name":"张腾文","title":"董事","isMale":false,"age":"50","degree":"博士","salary":"10.00万","stockAmount":"-","description":"张腾文女士,1970年出生,中国国籍,无境外居留权,公司董事,财务管理学博士,副教授,高级经济师,西南财经大学研究生导师。曾任职于攀钢集团公司经济发展研究中心、攀钢集团公司资本运营部和攀枝花新钢钒股份有限公司,从事过财务报告审查、投资项目价值评估、收购兼并、财务会计研究等工作。2012年7月至2015年6月任公司独立董事。2015年6月起任公司董事。目前兼任四川三台农村商业银行股份有限和成都盛帮密封件股份有限公司的独立董事,川商投产融控股有限公司董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_贺国生","group":"board","name":"贺国生","title":"董事","isMale":true,"age":"52","degree":"博士","salary":"7.500万","stockAmount":"-","description":"贺国生先生,1968年出生,中国国籍,无境外居留权,教授,硕士生导师,西南财经大学金融学博士,清华大学理学和经济学双学士。历任西南财经大学金融学院信用管理系系主任、西南财经大学证券与期货学院院长助理,现任西南财经大学证券与期货学院副院长。2014年至2015年四川科伦药业股份有限公司监事。现拟任公司董事。","lastUpdated":"2019-04-13"},{"id":"四川科伦药业股份有限公司_张涛","group":"board","name":"张涛","title":"独立董事","isMale":true,"age":"50","degree":"硕士","salary":"10.00万","stockAmount":"-","description":"张涛先生1970年出生,中国国籍,身份证号:320502197006181559,硕士研究生学历,加拿大永久居留权。1993年至2008年历任华泰证券股份有限责任公司投资银行部总监、上海机构客户营业部总经理、国际业务部总经理、债券部总经理、股票交易部高级经理等;2008年至2010年任上海磐石投资管理有限公司执行总裁;2010年至今任熔安德(天津)投资合伙企业(有限合伙)创始人。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_王广基","group":"board","name":"王广基","title":"独立董事","isMale":true,"age":"67","degree":"博士","salary":"10.00万","stockAmount":"-","description":"王广基先生,男,1953年4月出生,博士、博士后、教授、博士生导师,中国工程院院士,中共党员。原中国药科大学副校长。现任金陵药业股份有限公司独立董事、董事会提名委员会主任委员,中国药科大学学术委员会主任,江苏省药物代谢动力学重点实验室主任、国家中医药管理局整体药代动力学重点研究室主任等职。并任中国药学会应用药理专业委员会主任委员、中国药理学会制药工业专业委员会主任委员等职。兼任四川科伦药业股份有限公司、江苏恩华药业股份有限公司独立董事,吉林亚泰(集团)股份有限公司、江苏联环药业股份有限公司、南京广陵医药科技有限责任公司董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_李越冬","group":"board","name":"李越冬","title":"独立董事","isMale":false,"age":"43","degree":"博士","salary":"10.00万","stockAmount":"-","description":"李越冬,女,1977年1月出生,会计专业博士,教授,曾任中国建设银行会计。现任西南财经大学会计学院审计系副主任;四川省审计学会理事;四川省会计学会理事;成都市审计学会副会长;常务理事;成都市商务委咨询专家;成都文彰教育咨询有限公司董事;四川科伦药业股份有限公司及成都高新发展股份有限公司独立董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_万鹏","group":"supervisoryCommittee","name":"万鹏","title":"监事会主席","isMale":true,"age":"44","degree":"硕士","salary":"0.00","stockAmount":"-","description":"万鹏先生,1976年出生,中国国籍,无境外居留权,公司监事会主席,公司法律事务部总监,研究生学历,2001年司法部授予全国律师资格。2001年10月加入公司前身四川科伦大药厂,任职资产保全部,自2007年12月至今任四川科伦药业股份有限公司法律事务部总监。2015年3月起任公司监事会主席。现兼任四川科伦实业集团有限公司监事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_郭云沛","group":"supervisoryCommittee","name":"郭云沛","title":"监事","isMale":true,"age":"73","degree":"大专","salary":"10.00万","stockAmount":"-","description":"郭云沛,1947年7月出生,中国国籍,无境外永久居留权,大专学历,高级编辑。曾担任中国医药报社副总编辑以及报社第一负责人、北京卓信医学传媒集团执行总裁、中国医药企业管理协会副会长、会长。2008年至今,任中国医药企业管理协会名誉会长、专家委员会执行主任。2015年11月至今,任北京玉德未来控股有限公司董事。2016年6月至今,兼任公司董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_郑昌艳","group":"supervisoryCommittee","name":"郑昌艳","title":"职工监事","isMale":false,"age":"46","degree":"本科","salary":"0.00","stockAmount":"6.16万","description":"郑昌艳女士,1974年出生,中国国籍,无境外居留权,本科学历,1997年加入公司前身四川科伦大药厂,现任办公室主任兼人力资源部副总监。拟任四川科伦药业股份有限公司第六届监事会职工代表监事。","lastUpdated":"2018-04-12"},{"id":"四川科伦药业股份有限公司_刘思川","group":"manager","name":"刘思川","title":"总经理","isMale":true,"age":"36","degree":"硕士","salary":"160.0万","stockAmount":"709.9万","description":"刘思川先生,1984年出生,中国国籍,无境外居留权,公司董事,总经理,硕士研究生学历。2007年起任公司董事长助理,2009年6月起任公司董事,2012年7月起任公司副总经理,2015年9月起任公司总经理。2013年1月当选为湖南省第十二届人民代表大会代表,2018年1月当选为湖南省第十三届人民代表大会代表。现为中华全国青年联合会委员,中国青年志愿者协会常务理事、中国光华科技基金会第六届理事会理事,全国工商联执行委员,湖南省总商会副会长。目前兼任四川科伦实业集团有限公司董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_冯昊","group":"manager","name":"冯昊","title":"董事会秘书,副总经理","isMale":true,"age":"40","degree":"硕士","salary":"100.0万","stockAmount":"29.2万","description":"冯昊先生,1980年出生,中国国籍,无境外居留权,公司副总经理兼董事会秘书,中共党员,硕士研究生学历。先后任华中科技大学经济学院教师,太平人寿保险有限公司精算部分析员、上海华信惠悦(咨询)有限责任公司精算咨询顾问、平安证券有限责任公司投资银行部高级经理、国金证券股份有限公司投资银行部业务董事。2014年4月起任公司副总经理兼董事会秘书。目前兼任石四药集团有限公司非执行董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_王晶翼","group":"manager","name":"王晶翼","title":"副总经理","isMale":true,"age":"60","degree":"博士","salary":"800.0万","stockAmount":"35.22万","description":"王晶翼先生,1960年出生,中国国籍,有境外居留权,公司副总经理、全球研发总裁、首席科学家、药物研究院院长,2015年9月起任公司董事。目前兼任四川科伦博泰生物医药股份有限公司董事长。中国医科大学77级临床医学本科,解放军第四军医大学传染病学硕士、医学分子病毒学博士。曾任美国阿肯色医科大学医学助理教授(Tenuretrack)、齐鲁制药有限公司集团副总经理和药物研究院院长,目前兼任《中国新药杂志》编委、国家科学技术奖励评审专家、重大新药创制国家科技重大专项评委等社会职务。近年来三次荣获国家科学技术进步二等奖。自2002年回国以来,王晶翼博士带领团队上市重大品种30余项,其中不乏卡培他滨等年销售额超过10亿的重磅药物,且有塞拉替尼等20余项创新药物相继步入临床研究。自2012年11月加盟科伦以后,在王晶翼院长的领导下,科伦的药物研究已从简单输液产品仿制研究转型为高技术内涵药物为主的研究;以“仿制为基础,创新驱动未来”的产品线战略布局全面达成;科伦已成为国内药品研发创新发展速度迅捷、体系完备的大型制药企业,成功构建了一支科学水平高、战斗意志强、与国际接轨的创新研发团队。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_赖德贵","group":"manager","name":"赖德贵","title":"副总经理,财务总监","isMale":true,"age":"49","degree":"本科","salary":"100.0万","stockAmount":"28.92万","description":"赖德贵先生,1971年出生,中国国籍,无境外居留权,公司副总经理兼财务总监,本科学历。先后任成都蓝风(集团)股份有限公司、成都蓝风集团(控股)有限公司会计、财务经理,2001年加入公司前身四川科伦大药厂任会计、财务部副经理,2006年起任公司会计机构负责人。2014年10月起任公司副总经理兼财务总监。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_万阳浴","group":"manager","name":"万阳浴","title":"副总经理","isMale":true,"age":"50","degree":"本科","salary":"100.0万","stockAmount":"20.5万","description":"万阳浴先生,1970年出生,中国国籍,无境外居留权,公司副总经理,中共党员,本科学历。曾任职于成都军医总医院药剂科负责灭菌制剂的生产质量管理,1998年进入公司前身四川科伦大药厂,任生产部车间主任,2000年任公司副总经理、生产部部长,2006年起任公司副总经理,负责生产管理。2015年参与项目荣获国家科技进步二等奖。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_葛均友","group":"manager","name":"葛均友","title":"副总经理","isMale":true,"age":"48","degree":"博士","salary":"100.0万","stockAmount":"27.5万","description":"葛均友先生,1972年出生,中国国籍,无境外居留权,公司副总经理,复旦大学博士研究生学历,执业药师,高级工程师。曾任上海延安制药厂生产主管,上海恒寿堂药业有限公司生产技术部副经理,上海勃林格殷格翰药业有限公司GMP监督,浙江海正药业股份有限公司总经理助理,德国RATIOPHARM制药有限公司亚太区质量经理。现为国家食品药品监督管理总局高级研修学院特聘教授,四川省执业药师协会副会长,成都药学会生产质量委员会主任委员。2007年6月起任公司质量总监,2009年6月起任公司副总经理,负责质量管理。目前兼任四川科伦斗山生物技术有限公司董事。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_卫俊才","group":"manager","name":"卫俊才","title":"副总经理","isMale":true,"age":"56","degree":"本科","salary":"100.0万","stockAmount":"22.56万","description":"卫俊才先生,1964年出生,中国国籍,无境外居留权,公司副总经理,大学本科学历,高级营销师。先后任四川省第三人民医院、深圳海王药业等单位医师、高级营销经理、营销总监等职务。2008年先后任公司招投标事务部总经理和市场与招投标部总监,主管公司政策研究及市场准入工作,2012年7月起任公司副总经理。2015年参与项目荣获国家科技进步二等奖。现为中国卫生法学会副会长、中国化学制药工业协会注射剂专委会秘书长、四川省医疗保险研究会常务理事、四川省政协社会与法制专业委员会特邀成员、成都市医疗保险研究会副会长。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_谭鸿波","group":"manager","name":"谭鸿波","title":"副总经理","isMale":true,"age":"49","degree":"本科","salary":"100.0万","stockAmount":"24.5万","description":"谭鸿波先生,1971年出生,中国国籍,无境外居留权,公司副总经理,大学本科,高级工程师,无党派。曾任职于成轴集团公司轴承检测西南分中心,从事技术管理工作;1996年起加入公司前身四川科伦大药厂;2006年起任四川科伦药业股份有限公司新都基地总经理;成都市新都区第十七届人大常委会委员。2001年荣获成都市新都区人民政府颁发“成都市新都区科技进步特等奖”,2002年荣获成都市人民政府颁发“成都市科技进步二等奖”,2006年四川省质量技术监督局授予“四川省质量管理先进工作者”荣誉称号,2011年荣获四川省人民政府、成都市人民政府颁发的“四川省科技进步一等奖”、“成都市科技进步特等奖”,2015年参与项目荣获国家科技进步二等奖。2013年6月起任公司副总经理。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_戈韬","group":"manager","name":"戈韬","title":"副总经理","isMale":true,"age":"40","degree":"本科","salary":"100.0万","stockAmount":"18万","description":"戈韬先生,1980年出生,中国国籍,无境外居留权,公司副总经理,成都药学会理事,本科学历。1999年进入公司前身四川科伦大药厂销售服务部工作,2003年起任公司营销管理部执行总经理,负责东北、华北区域覆盖八省区的营销管理工作。2015年2月起任公司副总经理。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_吴中华","group":"manager","name":"吴中华","title":"副总经理","isMale":true,"age":"52","degree":"本科","salary":"100.0万","stockAmount":"14.5万","description":"吴中华先生,1968年出生,中国国籍,无境外居留权,公司副总经理,中共党员,大学本科学历,机械工程师、执业药师和高级经济师,中国共产党安阳市第十三届人民代表大会代表。曾供职于湖南省岳阳市制药二厂、湖南天御龙药业有限公司。2004年任湖南中南科伦药业有限公司生产部长,先后任四川珍珠制药有限公司总经理、河南科伦药业有限公司总经理。2016年1月起任科伦药业副总经理。","lastUpdated":"2018-06-01"},{"id":"四川科伦药业股份有限公司_丁南超","group":"manager","name":"丁南超","title":"副总经理","isMale":true,"age":"34","degree":"本科","salary":"--","stockAmount":"-","description":"丁南超先生,1986年出生,中国国籍,无境外居留权,中共党员,西南交通大学毕业,大学本科学历,学士学位。2008年入职科伦药业,先后任公司营销管理部区域销售助理、经理、副总监,新药销售部销售总监。2020年4月起拟任公司副总经理,分管新药营销板块。","lastUpdated":"2020-04-28"}],"companyName":"四川科伦药业股份有限公司","province":"四川省","englishName":"Sichuan Kelun Pharmaceutical Co Ltd","industry":"医药生物 — 化学制药","website":"www.kelun.com","mainBusiness":"输液系列药品的开发、生产和销售","productsName":["镇痛麻醉类","精神类","抗病原微生物类","营养输液","呼吸类","心脑血管类","抗肿瘤类","抗骨质疏松类","水电解质平衡类"],"actualController":"刘革新","actualControllerSharePercentage":"26.33%","registeredCapital":"14.39亿元","employeeAmount":"20242","phone":"86-028-82860516;86-028-82860678","location":"四川省成都市青羊区百花西路36号","chineseDescription":"四川科伦药业股份有限公司是主要从事大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等25种剂型药品及抗生素中间体、原料药、医药包材、医疗器械等产品的研发、生产和销售。主要产品涵盖麻醉镇痛、中枢神经、抗感染、肠外营养等领域。三年来，已实现41项仿制药连续获批上市，16个品种通过一致性评价，2个品种创新药物开展中美临床研究，新一代肿瘤免疫药物A293获批临床，首个创新药物A167完成关键II期临床疗效评估。公司作为国内医药创新和高质量发展的代表企业，荣获“中国制药集团研发20强”、“2019年中国医药研发产品线最佳工业企业...查看全部▼四川科伦药业股份有限公司是主要从事大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等25种剂型药品及抗生素中间体、原料药、医药包材、医疗器械等产品的研发、生产和销售。主要产品涵盖麻醉镇痛、中枢神经、抗感染、肠外营养等领域。三年来，已实现41项仿制药连续获批上市，16个品种通过一致性评价，2个品种创新药物开展中美临床研究，新一代肿瘤免疫药物A293获批临床，首个创新药物A167完成关键II期临床疗效评估。公司作为国内医药创新和高质量发展的代表企业，荣获“中国制药集团研发20强”、“2019年中国医药研发产品线最佳工业企业”等荣誉称号。收起▲","foundedDate":"2002-05-29","goPublicDate":"2010-06-03","companyHistory":"四川科伦药业股份有限公司(以下简称“本公司”)是在中华人民共和国四川省成都市成立的股份有限公司，总部位于四川省成都市。本公司的最终实际控制人为刘革新先生。\n　　于2016年1月13日，本公司子公司湖北科伦成立湖北科伦医贸；于2016年6月17日，本公司成立子公司新开元；于2016年6月25日，本公司子公司湖南科伦成立湖南研究院；于2016年8月17日，本公司子公司科伦研究院成立科伦晶川；于2016年，本公司子公司科伦研究院的子公司科伦晶川成立科伦汇智、科伦汇德、科伦汇能、科伦汇才；于2016年8月30日，本公司子公司科伦国际发展成立科伦国际医药；于2016年9月30日，本公司子公司科伦国际发展的子公司科伦国际医药成立科纳斯制药；于2016年10月8日，本公司子公司伊犁川宁收购瑾禾生物及其子公司盈辉贸易；于2016年11月22日，科伦汇智、科伦汇德、科伦汇能、科伦汇才共同成立博泰生物，于2016年12月12日，本公司子公司科伦研究院的子公司科伦晶川成立科伦智才；于2016年12月12日，本公司子公司科伦研究院的子公司科伦晶川成立科伦德能；于2016年12月28日，本公司注销分公司简阳分公司。\n　　于2018年1月22日，本公司成立科伦农业。\n　　于2018年3月26日，本公司子公司湖北科伦收购湖北科伦医贸15%的少数股东权益，湖北科伦持有湖北科伦医贸全部股权。\n　　于2018年4月18日，本公司收购新疆医药公司10%的少数股东权益，四川科伦持有新疆医药公司全部股权。\n　　于2018年6月12日，本公司成立上海科伦医药。\n    于2018年11月2日，本公司子公司君健塑胶成立四川科圣嘉医疗。收起▲","shareholders":[{"organizationId":"","holderName":"刘革新","totalShare":"3.79亿","sharePercentage":"26.33%"},{"organizationId":"","holderName":"潘慧","totalShare":"1.52亿","sharePercentage":"10.57%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"3712.29万","sharePercentage":"2.58%"},{"organizationId":"","holderName":"程志鹏","totalShare":"2628.98万","sharePercentage":"1.83%"},{"organizationId":"","holderName":"重庆国际信托股份有限公司-创赢投资10号集合资金信托计划","totalShare":"2265.06万","sharePercentage":"1.57%"},{"organizationId":"","holderName":"招商银行股份有限公司-睿远成长价值混合型证券投资基金","totalShare":"1636.20万","sharePercentage":"1.14%"},{"organizationId":"","holderName":"刘亚光","totalShare":"1511.99万","sharePercentage":"1.05%"},{"organizationId":"","holderName":"尹凤刚","totalShare":"1445.85万","sharePercentage":"1.00%"},{"organizationId":"","holderName":"王萍","totalShare":"1424.38万","sharePercentage":"0.99%"},{"organizationId":"","holderName":"潘渠","totalShare":"1416.74万","sharePercentage":"0.98%"}],"englishDescription":"SICHUAN KELUN PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The Company operates its businesses through manufacture and distribution of injections, booster injections, lyophilized power injections, tablets, capsules, granules, oral liquids, dialysis fluids and other form of pharmaceuticals, bulk pharmaceutical chemicals, pharmaceutical packing materials, as well as medical equipment. The Company's injection products include general injections and therapeutic injections, such as glucose injections, sodium chloride injections, glucose and sodium chloride injections, ofloxacin injections, metronidazole injections and norfloxacin injections, among others. Through its subsidiaries, it also engages in the manufacture of rubber and plastic products. The Company distributes its products within domestic market and to overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"51.84","Price to sales (ttm)":"1.91","Price to book (mrq)":"2.46","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"87.90","Lt debt to equity (mrq)":"26.92","Return on investment (ttm)":"3.93","Return on equity (ttm)":"2.21","Income statement":{"Revenue":"17,636.27","Total revenue":"17,636.27","Cost of revenue, total":"7,063.87","Gross profit":"10,572.39","Selling/general/admin. expenses, total":"7,680.35","Research & development":"1,220.44","Depreciation/amortization":"185.89","Interest exp.(inc.),net-operating, total":"374.30","Unusual expense (income)":"19.80","Other operating expenses, total":"(185.27)","Total operating expense":"16,359.39","Operating income":"1,276.88","Other, net":"(20.58)","Net income before taxes":"1,256.29","Provision for income taxes":"234.75","Net income after taxes":"1,021.54","Minority interest":"(83.69)","Net income before extra. items":"937.86","Net income":"937.86","Income available to com excl extraord":"937.86","Income available to com incl extraord":"937.86","Diluted net income":"937.86","Diluted weighted average shares":"1,439.79","Diluted eps excluding extraord items":"0.65","Dps - common stock primary issue":"0.43","Diluted normalized eps":"0.66","Gain (loss) on sale of assets":"(4.37)"},"Balance sheet":{"Cash":"1.12","Cash & equivalents":"2,192.75","Cash and short term investments":"2,193.87","Accounts receivable - trade, net":"6,480.66","Total receivables, net":"8,077.03","Total inventory":"3,386.23","Prepaid expenses":"457.75","Other current assets, total":"59.56","Total current assets":"14,174.43","Property/plant/equipment, total - gross":"17,304.51","Accumulated depreciation, total":"(4,876.66)","Property/plant/equipment, total - net":"12,427.85","Goodwill, net":"158.45","Intangibles, net":"1,480.87","Long term investments":"2,762.45","Other long term assets, total":"481.33","Total assets":"31,485.37","Accounts payable":"1,654.88","Accrued expenses":"378.26","Notes payable/short term debt":"4,394.27","Current port. of  lt debt/capital leases":"5,084.31","Other current liabilities, total":"3,308.65","Total current liabilities":"14,820.37","Long term debt":"2,146.56","Total long term debt":"2,146.56","Total debt":"11,625.13","Deferred income tax":"247.98","Minority interest":"717.99","Other liabilities, total":"364.42","Total liabilities":"18,297.32","Common stock, total":"1,439.79","Additional paid-in capital":"3,549.50","Retained earnings (accumulated deficit)":"8,447.96","Treasury stock - common":"(380.30)","Other equity, total":"131.11","Total equity":"13,188.05","Total liabilities & shareholders' equity":"31,485.37","Total common shares outstanding":"1,439.79","Tangible book value per share, common eq":"8.02"},"Cash flow":{"Cash receipts":"19,864.05","Cash payments":"(13,311.18)","Cash taxes paid":"(1,739.43)","Changes in working capital":"(2,596.70)","Cash from operating activities":"2,216.74","Capital expenditures":"(1,331.04)","Other investing cash flow items, total":"(28.30)","Cash from investing activities":"(1,359.33)","Financing cash flow items":"(90.92)","Total cash dividends paid":"(849.10)","Issuance (retirement) of debt, net":"472.03","Cash from financing activities":"(467.99)","Foreign exchange effects":"2.22","Net change in cash":"391.63"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"22.47","52 Week High":"33.50","52 Week Low":"18.89","Pricing date":"","10 Day Average Trading Volume":"17.68","Market Capitalization":"32,327.38","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"330.81","Beta":"0.73","1 Day Price Change":"-1.06","13 Week Price Return (Daily)":"15.53","26 Week Price Return (Daily)":"-10.12","5 Day Price Return (Daily)":"5.25","52 Week Price Return (Daily)":"-28.39","Year To Date Price Return (Daily)":"-4.34","Month to Date Price Return (Daily)":"7.00","Price Relative to S&P500 (4 Week)":"-7.31","Price Relative to S&P500 (13 Week)":"-9.18","Price Relative to S&P500 (26 Week)":"-29.60","Price Relative to S&P500 (52 Week)":"-51.34","Price Relative to S&P500 (YTD)":"-26.84"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.65","EPS excl. Extra Items (TTM)":"0.43","EPS Normalized (Annual)":"0.66","Revenue per Share (Annual)":"12.25","Revenue per Share (TTM)":"11.73","Book Value (Per Share Annual)":"9.16","Book Value (Per Share Quarterly)":"9.12","Tangible Book Value (Per Share Annual)":"8.02","Tangible Book Value (Per Share Quarterly)":"7.96","Cash Per Share (Per Share Annual)":"1.52","Cash Per Share (Per Share Quarterly)":"2.16","Cash Flow (Per Share Annual)":"1.46","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.43","Dividends (Per Share TTM)":"0.43","EBITD (Per Share TTM)":"0.96","EPS Basic excl. Extra Items (Annual)":"0.65","EPS Basic excl. Extra Items (TTM)":"0.43","EPS incl. Extra Items (Annual)":"0.65","EPS incl. Extra Items (TTM)":"0.43","Free Cash Flow (Per Share TTM)":"-0.41","Dividend (Per Share 5Y)":"0.22"},"Valuation":{"P/E excl. Extra Items (Annual)":"34.50","P/E excl. Extra Items (TTM)":"51.84","P/E Normalized (Annual)":"33.91","Price to sales (Annual)":"1.83","Price to sales (TTM)":"1.91","Price to Tangible Book (Annual)":"2.80","Price to Tangible Book (Quarterly)":"2.82","Price to Free Cash Flow (Per Share Annual)":"883.12","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"2.45","Price to Book (Quarterly)":"2.46","P/E Basic excl. Extra Items (TTM)":"47.74","P/E excl. Extra Items High (TTM)":"60.27","P/E excl. Extra Items Low (TTM)":"24.51","P/E incl. Extra Items (TTM)":"51.84","Net Debt (Interim)":"8,435.83","Net Debt (Annual)":"9,431.27","Dividend Yield (5Y)":"1.08","Dividend Yield":"1.89","Current Dividend Yield (TTM)":"1.89"},"Financial Strength":{"Free Cash Flow (Annual)":"36.61","Current Ratio (Annual)":"0.96","Net Interest coverage (Annual)":"4.46","Long Term Debt/Equity (Annual)":"16.28","Payout Ratio (Annual)":"64.26","Quick Ratio (Annual)":"0.73","Total Debt/Total Equity (Annual)":"88.15","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.04","Long Term Debt/Equity (Quarterly)":"26.92","Quick Ratio (Quarterly)":"0.81","Total Debt/Total Equity (Quarterly)":"87.90","Free Cash Flow (TTM)":"-591.43","Net Interest Coverage (TTM)":"3.08","Payout Ratio (TTM)":"96.57"},"Margins":{"Gross Margin (Annual)":"59.95","Gross Margin (TTM)":"57.48","Net Profit Margin % (Annual)":"5.79","Net Profit Margin (TTM)":"4.09","Operating Margin (Annual)":"7.24","Operating Margin (TTM)":"5.49","Pretax Margin (TTM)":"5.27","Pretax Margin (Annual)":"7.12","Operating Margin (5Y)":"8.12","Pretax Margin (5Y)":"8.30","Free Operating Cash Flow/Revenue (5Y)":"-3.12","Free Operating Cash Flow/Revenue (TTM)":"-3.50","Gross Margin (5Y)":"53.24","Net Profit Margin (5Y)":"6.91"},"Management Effectiveness":{"Return on Assets (Annual)":"3.36","Return on Equity (TTM)":"2.21","Return on Average Equity (Annual)":"7.23","Return on Average equity (TTM)":"4.78","Return on Investment (Annual)":"5.88","Return on Investment (TTM)":"3.93","Return on Average Assets (5Y)":"3.29","Return on Average Equity (5Y)":"7.01","Return on Investment (5Y)":"5.46","Asset Turnover (Annual)":"0.58","Asset Turnover (TTM)":"0.54","Inventory Turnover (Annual)":"2.22","Inventory Turnover (TTM)":"2.29","Net Income/Employee (Annual)":"50,782.52","Net Income/Employee (TTM)":"34,131.22","Receivables Turnover (Annual)":"2.90","Receivables Turnover (TTM)":"2.61","Revenue/Employee (Annual)":"876,728.30","Revenue/Employee (TTM)":"834,208.70"},"Growth":{"Revenue Growth (Quarterly YoY)":"-17.50","Revenue Growth Rate (5Y)":"17.06","EPS Growth (Quarterly YoY)":"-93.48","EPS Growth (TTM YoY)":"-46.45","EPS Growth Rate (5Y)":"-1.31","Dividend Growth Rate (3Y)":"45.07","Revenue Growth (TTM YoY)":"1.07","Revenue Growth (Per Share 5Y)":"17.06","Revenue Growth Rate (3Y)":"27.22","EPS Growth Rate (3Y)":"16.86","Book Value Growth Rate (Per Share 5Y)":"4.20","Tangible Book Value Total Equity CAGR (5Y)":"4.05","Capital Spending growth rate 5 year":"-13.56","EBITDA CAGR (5Y)":"7.56","EBITDA Interim CAGR (5Y)":"1.34","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"15.01","Net Profit Margin Growth Rate (5Y)":"-13.94"},"Income Statement":{"Revenue (Annual)":"17,636.27","Revenue (TTM)":"16,886.05","EBITD (Annual)":"2,748.16","EBITD (TTM)":"1,379.21","Earnings Before Taxes (Annual)":"1,256.29","Earnings Before Taxes (TTM)":"889.26","Net Income to Common (Annual)":"937.86","Net Income to Common (TTM)":"624.06","Earnings Before Taxes Normalized (Annual)":"1,276.09","Net Income Available to Common Normalized (Annual)":"953.95","Diluted Normalized EPS excl. Extra Items (TTM)":"0.44"}}}